在患有帕金森病的患者中胸腔合后的伪关节炎
Matthew Lindsey1,2, Hannah Levy3, Tyler Allen3
1Division of Spine Surgery, Department of Orthopedics, St Louis University School of Medicine, Saint Louis, MO, USA.
Journal of spine surgery (Hong Kong)
|January 9, 2026
概括
胸椎合后的伪关节炎在帕金森病 (PD) 患者中很常见. 震,轮椅使用和较低的骨密度等因素增加了这种风险,导致死亡率更高.
科学领域:
- 脊柱外科手术 脊柱外科手术
- 神经学 神经学
- 整形外科 整形外科 整形外科
背景情况:
- 伪关节炎是脊柱形手术后的一个常见并发症.
- 帕金森病 (PD) 患者经历姿势不稳定和脊柱形,使脊柱融合复杂化.
- 脊柱融合在PD患者中具有很高的并发症风险,伪关节炎的特定风险因素尚未完全理解.
研究的目的:
- 在患有帕金森病的患者中,在胸腔关 (TL) 融合后与伪关节炎相关的患者特异性和操作因素的识别.
- 阐明在这个高风险人群中导致核聚变失败的风险因素.
主要方法:
- 成年PD患者进行后部TL融合 (2017-2022) 的回顾性病例控制研究.
- 收集的数据包括并发症,功能状态,PD指标,骨/肌肉质量,手术指示和构造细节.
- 在手术1年后通过CT扫描评估融合;单变量分析比较了融合和伪关节炎组之间的变量.
主要成果:
- 在59名PD患者中观察到27%的伪关节炎率.
- 伪关节炎与螺丝松动,90天和1年死亡率有显著的关联.
- 与震,较低的霍恩斯菲尔德单位 (骨密度),轮椅使用和创伤相关的伪关节炎风险增加.
结论:
- 帕金森病是TL脊髓融合后不良结果的重要危险因素.
- 诸如轮椅依赖,骨密度下降,基本震和创伤迹象等因素增加了伪关节炎的发生率.
- 在接受TL融合的PD患者中,伪关节炎与死亡率的增加有关.
更多相关视频
相关概念视频
Parkinson's Disease: Treatment
970
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
970
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K


